RECENT NEWS

Multi-mode ligand bioprocessing technology and advanced therapeutics

BIA Separations, a bio-chromatography development and manufacturing company, has introduced PrimaS ligand technology, a multi-use platform that facilitates high-resolution, high-speed processing and addresses critical separation problems.

Latest laboratory collaboration to provide precision oncology at scale

Dante Labs, Cambridge Cancer Genomics and Nonacus have formed a partnership that aims to build the most comprehensive and patient-centred tumour profiling service, enabling improved cancer patient management, treatment and monitoring.

MAGNUS: a game-changer in tissue processing

Menarini Diagnostic is expanding its cellular pathology portfolio with MAGNUS, the most advanced tissue processor on the market, which will allow users to achieve same-day diagnosis for urgent biopsies with minimal downtime and intervention.

Diagnostics for glycaemic monitoring and ketosis testing on show

EKF Diagnostics has announced that its online exhibition booth at ENDO Online 2020 is open for live chats on its range of diagnostics products for glycaemic monitoring and ketosis testing on 10–17 June.

Rapid reports and automated SNOMED coding in histopathology

The Department of Histopathology and Cytopathology at the Royal Sussex County Hospital recently deployed GHG Software Developments’ TalkingPoint speech-enabled Histopathology workflow solution to support efficient pathology reporting.

PiP App available: Pathology in Practice in action and on the move

Pathology in Practice is now available via Apps free both in the Google Play Store and the Apple App Store. The App provides access to the current and previous digital issues of Pathology in Practice, and copies of The Clinical Services Journal.

Digital pathology solution transforms approach to diagnostics and care

Royal Philips is enabling the University Hospital Crosshouse, Kilmarnock, to introduce remote digital pathology capabilities that will help the hospital best serve residents of Ayrshire and Arran, helping to set a new standard of diagnostic services.

Autoclave range gains Saudi Food & Drug Authority approval

As a leading British autoclave manufacturer, Priorclave is pleased to have gained approval from the Saudi Food & Drug Authority (SFDA) for its entire range of research-grade laboratory autoclaves.

Dotmatics receives certification for scientific informatics technology

Dotmatics, a scientific informatics software and services company that is driving the automation of laboratory data workflows has achieved certification to the internationally recognised standard ISO 9001:2015 for its quality management system (QMS).

Non-tuberculous mycobacteria: new digital educational resource

Insmed, a global company focused on the unmet needs of patients with rare disease, has launched NTM Action, an interactive digital resource aiming to increase awareness of non-tuberculous mycobacteria (NTM) among UK healthcare professionals.

TalkingPoint completes all-remote installation at Royal Gwent Hospital

With social distancing restrictions in place, TalkingPoint has completed a rapid ‘all-remote’ deployment of the TalkingPoint Pathology speech-enabled histopathology reporting workflow at the Royal Gwent Hospital, Aneurin Bevan Health Board.

CytoSMART Technologies launches the CytoSMART Lux2 Duo Kit

CytoSMART Technologies has launched a new live-cell imaging system. The CytoSMART Lux2 Duo Kit offers a straightforward, cost-effective solution for researchers carrying out immediate side-by-side comparisons between cell cultures.

Point-of-care analysers help to keep vulnerable patients safer in Cornwall

HORIBA UK, Medical has announced that the Royal Cornwall Hospitals NHS Trust (RCHT) in partnership with the Cornwall Foundation NHS Trust has recently purchased and installed five new Microsemi CRP point-of-care (POC) haematology analysers.

Medica 2020: commitment to UK presence in November

With the unprecedented circumstances caused by the coronavirus pandemic, there have been a number of questions as to whether or not Medica, the largest medical technology exhibition in the world, will go ahead this year. Messe Düsseldorf, the organisers of Medica, are still planning for the show to take place on 16–19 November, with Medilink UK and GAMBICA being committed to organising UK pavilions at the exhibition.

Gap between non-tuberculous mycobacteria testing behaviour and guidelines identified

A study published in BMJ Open Respiratory Research has revealed that, contrary to guideline recommendations, 68% of clinicians managing bronchiectasis patients do not test them for non-tuberculous mycobacteria (NTM) infection prior to starting macrolide treatment.

Distribution agreement expands HbA1c POC testing to the Middle East and Africa

EKF Diagnostics has signed a three-year distribution agreement with Tosoh Europe for the distribution of its Quo-Test HbA1c point-of-care (POC) analyser in the Middle East and Africa.

Strategic alliance provides automated workflows for prostate cancer diagnostics

Proteomedix, the Swiss cancer diagnostics company, and Dynex Technologies have announced a strategic partnership enabling Proteomedix to establish automated workflows for its prostate cancer diagnostics test, and to sell Dynex instruments to the global clinical market.

Xdrop and single-molecule target selection of genomic regions

Samplix has launched its comprehensive service programme to grant any laboratory access to the advantages of Xdrop technology. By partnering with the Samplix service team, researchers can make use of the unique Xdrop approach to address complex genomic questions, including gap closing, sequencing of repeat elements, detecting viral insertion sites, revealing unintended CRISPR edits, and more.

Anti-certolizumab pegol inhibitory antibodies

Bio-Rad Laboratories has launched a range of anti-certolizumab pegol inhibitory antibodies to support the development of assays for therapeutic drug monitoring of tumour necrosis factor-alpha (TNFα) inhibitors.

Novel biomarker for cancer therapy: a webinar

Genomic instability is a universal hallmark of all cancers. Many common chemotherapeutic agents target this genomic instability by directly damaging the DNA, resulting in tumour cell death. A new generation of drugs have been developed that inhibit the DNA repair enzyme PARP to induce DNA damage. Dr Joshua Burgess (Advance Queensland Early Career Research Fellow at the Translational Research Institute, Queensland University of Technology) will be leading a free webinar on Tuesday 12 May (3.00 pm BST, 10.00 am EST, 7.00 am PST). Click on this story to access the link to register.